Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Abstract

In this comprehensively adjusted analysis, vedolizumab concentrations at week 6 were associated with short- and long-term remission. Potential induction and maintenance target concentrations were proposed for further study.